Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer (Radiogenomics-Esophagus) (ECO)
Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shu Peng, doctor
- Phone Number: +8618571716422
- Email: drpeng90@hotmail.com
Study Locations
-
-
Other (Non U.s.)
-
Wuhan, Other (Non U.s.), China, 430030
- Recruiting
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Shu Peng, doctor
- Phone Number: +8618571716422
- Email: drpeng90@hotmail.com
-
Contact:
- Email: drpeng90@hotmail.com
-
Principal Investigator:
- Shu Peng, Doctor
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histopathologically diagnosed esophageal cancer
- Complete baseline clinical data available (including demographic characteristics, ECOG performance score, TNM staging, etc.)
- No other primary malignant tumors
- Provision of informed consent
- Availability of pre-treatment CT imaging
Exclusion Criteria:
- Imaging data quality insufficient for analysis
- Presence of another primary malignant tumor
- Severe systemic disease
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
neoadjuvant therapy cohort
received neoadjuvant therapy and esophagectomy
|
|
conservative treatment
concervative treatment includes chemo/immuno/radiotherapy and targeted theray
|
|
Endoscopic submucosal dissection (ESD)
|
|
Surgical resection cohort
neither neoajuvant therapy nor anti-tumor treatment prior to surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival
Time Frame: From enrollment to the end of treatment at 3 years
|
overall survival rate in 3-years
|
From enrollment to the end of treatment at 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4059393
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.